Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cefpodoxime Proxetil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 6/20 | 0.75 |
| ▸ | HTR2C | P28335 | 1/20 | 0.75 |
| ▸ | MAPT | P10636 | 3/20 | 0.66 |
| ▸ | PPARG | P37231 | 2/20 | 0.66 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.66 |
| ▸ | SLC22A8 | Q8TCC7 | 2/20 | 0.66 |
| ▸ | SLC22A11 | Q9NSA0 | 2/20 | 0.66 |
| ▸ | ALB | P02768 | 1/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.65 |
| ▸ | APEX1 | P27695 | 2/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cefpodoxime Proxetil SCHEMBL4410291 | 1.00 | PTGS1 (1.00) | PTGS1ABCB11PDE4DNR1I2HTR2C | |
| Cefpodoxime Proxetil SCHEMBL29465200 | 1.00 | PTGS1 (1.00) | PTGS1ABCB11PDE4DNR1I2HTR2C | |
| Cefpodoxime Proxetil SCHEMBL8687125 | 1.00 | PTGS1 (1.00) | PTGS1ABCB11PDE4DNR1I2HTR2C | |
| Cefpodoxime Proxetil SCHEMBL27071 | 1.00 | PTGS1 (1.00) | PTGS1ABCB11PDE4DNR1I2HTR2C | |
| Cefpodoxime Proxetil SCHEMBL379709 | 1.00 | PTGS1 (1.00) | PTGS1ABCB11PDE4DNR1I2HTR2C | |
| Cefpodoxime Proxetil SCHEMBL614583 | 1.00 | PTGS1 (1.00) | PTGS1ABCB11PDE4DNR1I2HTR2C | |
| Cefpodoxime Proxetil SCHEMBL7256264 | 1.00 | PTGS1 (1.00) | PTGS1ABCB11PDE4DNR1I2HTR2C | |
| Cefpodoxime Proxetil SCHEMBL7810065 | 1.00 | PTGS1 (1.00) | PTGS1ABCB11PDE4DNR1I2HTR2C | |
| Cefpodoxime Proxetil SCHEMBL22330291 | 1.00 | PTGS1 (1.00) | PTGS1ABCB11PDE4DNR1I2HTR2C | |
| Cefpodoxime Proxetil SCHEMBL5266189 | 0.99 | PTGS1 (0.99) | PTGS1ABCB11PDE4DNR1I2HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050250790-A1 | Novel sulfonic acid derivatives | PFIZER INC | 2005-11-10 | — | — | US | disclosed |
| EP-1045852-B1 | PROCESS FOR THE PREPARATION OF CEFPODOXIM PROXETIL DIASTEREOISOMERS | SANDOZ AG (CH) | 2005-10-26 | — | — | EP | disclosed |
| US-6949641-B2 | Crystalline β-lactam intermediate | SANDOZ AG (CH) | 2005-09-27 | — | — | US | disclosed |
| EP-1389187-A4 | PROCESS FOR THE PREPARATION OF CEFPODOXIME ACID | RANBAXY LAB LTD (IN) | 2005-03-16 | — | — | EP | disclosed |
| EP-1389187-A2 | PROCESS FOR THE PREPARATION OF CEFPODOXIME ACID | Ranbaxy Laboratories Limited (IN) | 2004-02-18 | — | — | EP | disclosed |
| US-6489470-B1 | A PROCESS FOR THE PRODUCTION OF A MIXTURE OF DIASTEREOISOMERS OF CEFPODOXIME PROXETIL BY ACYLATING A COMPOUND AND ACTIVATION THEN SPLITTING OFF | BIOCHEMIE GESELLSCHAFT M.B.H. (AT) | 2002-12-03 | — | — | US | disclosed |
| WO-2002083634-A2 | PROCESS FOR THE PREPARATION OF CEFPODOXIME ACID | RANBAXY LABORATORIES LIMITED (IN) | 2002-10-24 | — | — | WO | disclosed |
| US-20020065262-A1 | Crystalline beta-lactam intermediate | SANDOZ AG (FORMERLY BIOCHEMIE GMBH) (CH) | 2002-05-30 | — | — | US | disclosed |
| EP-1173444-A1 | CRYSTALLINE BETA-LACTAM INTERMEDIATE | BIOCHEMIE Gesellschaft m.b.H. (AT) | 2002-01-23 | — | — | EP | disclosed |
| EP-0484966-B1 | 7-Acyl-3-(substituted carbamoyloxy) cephem compounds, use thereof and process for their preparation | EISAI CO LTD (JP) | 2001-04-11 | — | — | EP | disclosed |
| EP-1074553-A1 | 7-Acyl-3-(substituted carbamoyloxy) cephem compounds, use thereof and process for their preparation | Eisai Co., Ltd. (JP) | 2001-02-07 | — | — | EP | disclosed |
| EP-1074554-A2 | 7-acyl-3-(substituted carbamoyloxy) cephem compounds, use thereof and process for their preparation | Eisai Co., Ltd. (JP) | 2001-02-07 | — | — | EP | disclosed |
| WO-2000066594-A1 | CRYSTALLINE BETA-LACTAM INTERMEDIATE | BIOCHEMIE GESELLSCHAFT M.B.H. (AT) | 2000-11-09 | — | — | WO | disclosed |
| EP-0761671-A1 | Cephem derivatives | Eisai Co., Ltd. (JP) | 1997-03-12 | — | — | EP | disclosed |
| US-5604217-A | CEPHALOSPORIN ANTIBIOTICS | EISAI CO., LTD. (JP) | 1997-02-18 | — | — | US | disclosed |
| US-5587473-A | BLOCKING; CONDENSATION; DEBLOCKING | EISAI CO., LTD. (JP) | 1996-12-24 | — | — | US | disclosed |
| US-5563265-A | BACTERICIDES | EISAI CO., LTD. (JP) | 1996-10-08 | — | — | US | disclosed |
| US-5559225-A | ANTIBIOTICS | EISAI CO., LTD. (JP) | 1996-09-24 | — | — | US | disclosed |
| EP-0484966-A2 | 7-Acyl-3-(substituted carbamoyloxy) cephem compounds, use thereof and process for their preparation | Eisai Co., Ltd. (JP) | 1992-05-13 | — | — | EP | disclosed |
| US-4482710-A | Process for preparing 3-alkoxymethylcephalosporin derivatives | SANKYO COMPANY LIMITED (JP) | 1984-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250790-A1 | Novel sulfonic acid derivatives | MSR1, MYD88, CXCR2 | PTGS1 757/4885ABCB11 711/4885PDE4D 2742/4885 |
| US-20020065262-A1 | Crystalline beta-lactam intermediate | CRYAA, CRYAB, CRYZ | PTGS1 4323/4885ABCB11 3486/4885PDE4D 3237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.